A phase III, randomized, double-blind, study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma Meeting Abstract
| Authors: | Salles, G.; Shah, H.; Leonard, J. P.; Szanto, A.; Chen, J.; Bannerji, R.; Morschhauser, F.; Nastoupil, L. J. |
| Abstract Title: | A phase III, randomized, double-blind, study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | epigenetics; follicular lymphoma; non-hodgkin lymphoma; phase iii; tazemetostat; ibcl; enhancer of zeste; homolog 2 protein |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S454 |
| End Page: | S455 |
| Language: | English |
| ACCESSION: | WOS:001062479600496 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01363-0 |
| Notes: | Meeting Abstract: IBCL-485 -- Source: Wos |
